AC2993 (synthetic exendin-4) Overview
Target population: People with type 2 diabetes
Currently in Phase 2 development
Phase 3 planned for 2H 2001, pending positive Phase 2 results
Exclusive world-wide rights to NIH patent applications
- Licensed in March 2001
- Claims include methods of conversion of non-insulin producing cells into insulin producing cells